Maraviroc for HIV: Responses at 48 Weeks
/
RSS Feed
Jacob Lalezari
REFERENCE:47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
JACOB LALEZARI, Quest Clinical Research, San Francisco
Maraviroc could be a useful new drug for the treatment of some HIV infections, according to Jacob Lalezari of Quest Clinical Research in San Francisco. He presented 48 week results from the MOTIVATE 1 study and Derek Thorne spoke to him at ICAAC in Chicago.
JACOB LALEZARI, Quest Clinical Research, San Francisco
Maraviroc could be a useful new drug for the treatment of some HIV infections, according to Jacob Lalezari of Quest Clinical Research in San Francisco. He presented 48 week results from the MOTIVATE 1 study and Derek Thorne spoke to him at ICAAC in Chicago.
You may also like...
Audio Journal of Medicine: Reporting from the 2006 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 27 – 30, San Francisco 1 Oct, 2006 - Visual Cervix Cancer Screening Test: Cheap and Effective in the Developing World 8 Aug, 2007
- Audio Journal of Hematologic Malignancy, Volume 2 Number 1 8 Jan, 2006
COVID-19 Co-Morbidity Risks Quantified from Three Continents Survey 28 May, 2020
